Nelfinavir is a protease inhibitor indicated for the treatment of HIV-1 infection. It is available as tablets for oral use. MedsAcross supplies Nelfinavir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
VIRACEPT in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection. VIRACEPT is a protease inhibitor indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents.
Source: US FDA prescribing information
Nelfinavir is an inhibitor of the HIV-1 protease.
Source: US FDA prescribing information
• See full prescribing information for administration instructions. • Adults and adolescents 13 years and older (tablets): 1250 mg twice daily or 750 mg three times daily with a meal. • Children 2 to less than 13 years (oral powder or 250 mg tablets): 45 to 55 mg/kg twice daily or 25 to 35 mg/kg three times daily with a meal. Refer to Tables 1 and 2 of the full prescribing information for specific dosing guidelines based on age and body weight
Source: US FDA prescribing information
Coadministration of VIRACEPT is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. These drugs and other contraindicated drugs (which may lead to reduced efficacy of nelfinavir) are listed in Table 3 [also see Drug Interactions, Table 6 ]. Table 3: Drugs That Are Contraindicated With VIRACEPT Drug Class Drugs Within Class That Are Contraindicated With VIRACEPT Clinical Comment Alpha 1-adrenoreceptor antagonist Alfuzosin Potentially increased alfuzosin concentrations can result in hypotension.
Source: US FDA prescribing information
ALERT: Find out about medicines that should not be taken with VIRACEPT. This statement is included on the product's bottle label. ALERT: Find out about medicines that should not be taken with VIRACEPT. • The concomitant use of VIRACEPT and certain other drugs may result in known or potentially significant drug interactions. Consult the full prescribing information prior to and during treatment for potential drug interactions. • Hepatic impairment: should not be used in patients with either moderate or severe hepatic impairment. • Phenylketonuria: the oral powder contains 11.2 mg phenylalanine per gram of powder. • Diabetes mellitus/hyperglycemia: new onset or exacerbation of pre-existing diabetes mellitus and hyperglycemia reported with protease inhibitors. In some cases after treatment discontinuation, hyperglycemia persisted.
Source: US FDA prescribing information
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. • Most common adverse reactions (≥2%) of moderate or severe intensity in adults and adolescents (13 years and older) are diarrhea, nausea, rash, and flatulence. • Most common adverse reactions in pediatric patients (2 to less than 13 years) are diarrhea, leukopenia/neutropenia, rash, anorexia, and abdominal pain.
Source: US FDA prescribing information
• Coadministration of VIRACEPT with other drugs ( CYP3A substrates) can alter the concentration of these other drugs, and other drugs (inhibitors and/or inducers of CYP3A or CYP2C19) may alter the concentrations of nelfinavir. The potential drug-drug concentrations must be considered prior to and during therapy. • VIRACEPT should be given with food one hour after or more than 2 hours before didanosine
Source: US FDA prescribing information
VIRACEPT tablets and oral powder should be stored at 15° to 30°C (59° to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Nelfinavir, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Viracept 250 mg tabletOral | Agouron | US FDA | Available on request |
| Viracept 625 mg tabletOral | Agouron | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Nelfinavir in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Nelfinavir and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Nelfinavir, including Viracept.
Yes. The US FDA first approved Nelfinavir on 14 March 1997, according to Drugs@FDA.
No listed presentation of Nelfinavir is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Nelfinavir is classified under ATC code J05AE04 (Nelfinavir).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.